Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Comparing mRNA expression between carrier treated and sorafenib treated Myc/NrasG12V liver tumors

ABSTRACT: To profile determinants of sensitivity and resistance towards the multikinase inhibitor sorafenib in liver cancer (HCC), we generated HCCs with elevated MYC expression and activated Raf-MEK-ERK signaling. To trigger tumor development, we co-delivered transposable elements encoding for Myc and oncogenic NrasG12V via hydrodynamic injection into the hepatocytes of C57BL/6 wildtype mice. To characterize the response of Myc/NrasG12V HCCs towards sorafenib, we analyzed their transcriptomes after three weeks of sorafenib or carrier treatment.

ORGANISM(S): Mus musculus

PROVIDER: GSE162322 | GEO | 2020/12/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Comparing mRNA expression of Myc/NrasG12V and Myc/Akt1 driven liver tumors

Project description:To analyze mRNA expression of Myc/NrasG12V and Myc/Akt1 driven liver tumors (HCC), we generated HCCs with elevated MYC expression and activated Raf-MEK-ERK or Akt1 signaling. To trigger tumor development, we co-delivered transposable elements encoding for Myc and oncogenic NrasG12V or myristoylated Akt1 via hydrodynamic injection into the hepatocytes of C57BL/6 wildtype mice and analyzed the transcriptomes of the developed tumors.

2020-12-01 | GSE162324 | GEO

Comparing mRNA expression between carrier treated and sorafenib treated Myc/NrasG12V liver tumors

Project description:Comparing mRNA expression between carrier treated and sorafenib treated Myc/NrasG12V liver tumors

| PRJNA681522 | ENA

NRASG12V mediates leukemia self renewal [Microarray]

Project description:Mutant RAS oncoproteins activate signaling molecules that drive oncogenesis in multiple human tumors including acute myelogenous leukemia (AML). However, the specific function of these pathways in AML is unclear. To elucidate the downstream functions of activated NRAS in AML, we employed a murine model of AML harboring Mll-AF9 and NRASG12V. We found that NRASG12V enforced leukemia self-renewal gene expression signatures and was required to maintain an MLL-AF9 and MYB-dependent gene expression program. In a multiplexed analysis of RAS-dependent signaling intermediates, the leukemia stem cell compartment was preferentially sensitive to RAS withdrawal. Use of RAS-pathway inhibitors showed that NRASG12V maintained leukemia self-renewal through mTOR and MEK pathway activation, implicating these pathways as potential targets for cancer stem cell-specific therapies. Mice harboring NRASG12V/Mll-AF9 AML were treated with doxycyline to abolish NRASG12V expression. Leukemia samples were harvested at 12 hour intervals after doxycyline treatment. RNA was extracted from these samples and submitted for gene expression microarray analysis

2014-11-16 | E-GEOD-49038 | biostudies-arrayexpress

NRASG12V mediates leukemia self renewal [RNA-Seq]

2014-11-16 | E-GEOD-49088 | biostudies-arrayexpress

NRASG12V mediates leukemia self renewal [Microarray]

2014-11-16 | GSE49038 | GEO

NRASG12V mediates leukemia self renewal [RNA-Seq]

2014-11-16 | GSE49088 | GEO

NRASG12V mediates self renewal in AML [RNA-Seq]

2014-11-16 | GSE49087 | GEO

NRASG12V mediates self renewal in AML [RNA-Seq]

Project description:Mutant RAS oncoproteins activate signaling molecules that drive oncogenesis in multiple human tumors including acute myelogenous leukemia (AML). However, the specific function of these pathways in AML is unclear. To elucidate the downstream functions of activated NRAS in AML, we employed a murine model of AML harboring Mll-AF9 and NRASG12V. We found that NRASG12V enforced leukemia self-renewal gene expression signatures and was required to maintain an MLL-AF9 and MYB-dependent gene expression program. In a multiplexed analysis of RAS-dependent signaling intermediates, the leukemia stem cell compartment was preferentially sensitive to RAS withdrawal. Use of RAS-pathway inhibitors showed that NRASG12V maintained leukemia self-renewal through mTOR and MEK pathway activation, implicating these pathways as potential targets for cancer stem cell-specific therapies. Primary NRASG12V-Mll-AF9 AML cells were treated in vitro for 24 hours with Ras-pathway inhibitors. RNA was extracted from these cells and submitted for RNA sequencing.

2014-11-16 | E-GEOD-49087 | biostudies-arrayexpress

Comparing mRNA expression of Myc/NrasG12V and Myc/Akt1 driven liver tumors

Project description:Comparing mRNA expression of Myc/NrasG12V and Myc/Akt1 driven liver tumors

| PRJNA681524 | ENA

Human osteosarcoma cells respond to sorafenib chemotherapy by downregulation of the tumor progression factors S100A4, CXCR4 and the oncogene FOS

Project description:Osteosarcoma is a rare but aggressive bone neoplasm in humans, which is commonly treated with surgery, classical chemotherapy and radiation. Here, we studied the antimetastatic potential of 4 M-NM-<M of the multikinase inhibitor Sorafenib in a human osteosarcoma cell line using DNA microarray-based gene expression profiling. 3 untreated replicates of human osteosarcoma cells (ATCC CRL-1543M-bM-^DM-"), 3 replicates of human osteosarcoma cells (ATCC CRL-1543M-bM-^DM-") treated with 4 M-BM-5M Sorafenib

2013-12-13 | E-GEOD-53155 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data